Set to help people suffering from high cholesterol. A Yorkshire life sciences company is set to save lives by developing an antibiotic for high cholesterol.
OptiBiotix Health, which develops products to combat high cholesterol, obesity, and diabetes as well as skincare, is pleased to announce that its wholly-owned subsidiary, ProBiotix, has released a third human-based study of its probiotic for lowering cholesterol Lactobacillus Plantarum ECGC13110402 and is marketed as LPLDL.
The statement read: “Previous studies have shown that LPLDL was not harmful and that the higher the cholesterol levels are, the more the reduction in cholesterol.
“The purpose of this study was to collect additional data on a different group of people of adults who are hypercholesterolemic. They are likely to gain from the cholesterol-lowering effect. They are also the best commercial value group to researchers examining the possibility for LPLD as an over-the-counter (OTC) natural medical product and drug therapy.
It was a follow-up of nine weeks single-center double-blind, randomized, human intervention trial placebo-controlled. The participants were assigned either one of two placebo or active treatments.
The study’s results indicated that at the end of six weeks, participants using placebo were compared to those who were taking LPLDL and LPLDL, there were statistically significant improvements to the risk of cardiovascular disease that is clinically significant, including a 34.2 percent decrease in total cholesterol as well as a 28.4 percent decrease in LDL cholesterol, also commonly referred to by the name terrible cholesterol.
The statement also stated, “No safety or tolerance, compliance or concerns were reported by participants during the study. The findings of this non-biased blinded, controlled study provide additional evidence of the potential of LPLD to reduce clinically significant cardiovascular risk factors in people with elevated cholesterol levels.”
Stephen O’Hara, CEO of OptiBiotix and OptiBiotix, said: “We are excited by the results of this study that show the statistically essential reductions of the number of cardiovascular risk factors, without issues with compliance, tolerance, or safety concerns.
“These results, together with studies conducted in the past and user feedback, suggest a possible application for probiotics such as LPLDL for people with high cholesterol levels who are unable or unwilling to take current treatments. With the potential for market growth and potential drawbacks of existing treatments, the commercial opportunity for LPLDL as a stand-alone treatment or when combined with other strategies is promising.”
Help support The Yorkshire Post and become an active subscriber today. Your subscription will enable us to continue to bring high-quality news to the residents of Yorkshire. In return, you’ll notice fewer advertisements on the site, have access for free to our app, and be eligible for exclusive member-only deals.
Please, should you be able to contribute to our work? The monthly payment of just PS5 is the base. If you feel that the goal we’re trying to accomplish is more valuable, then you could pay us what you are worth. In doing this, you will be taking part in something increasingly scarce. Independent journalism doesn’t care about left and right and more about wrong and right. Journalism that you can count on.